1. Is a good quality company?
Data is not available for this company.
2. Is undervalued or overvalued?
No data found
3. Is a good buy now?
No data found
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||20.8%||18%||15.4%||8.9%||2.1%||1.2%||-0.4%||-0.2%||0.2%||4.2%||-|
|Value Creation Index ⓘ||0.5||0.3||0.1||-0.4||-0.9||-0.9||-1.0||-1.0||-1.0||-0.7||-|
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||38.5%||36.4%||29.4%||12.6%||20.5%||1.6%||0.2%||13.8%||11.6%||-|
|Adj EPS ⓘ||26.1||29.2||33.3||26.8||-8.7||-13.3||-27.4||-24.6||-22.3||2.8||11.6|
|YoY Gr. Rt. %||-||12.2%||13.9%||-19.7%||-132.7%||NA||NA||NA||NA||NA||-|
|BVPS (₹) ⓘ||104.5||118.6||159.1||226.2||239.8||280.3||333.2||316||294.7||289.9||56.7|
|Adj Net Profit ⓘ||408||457||521||494||-165||-323||-667||-598||-542||68.1||182|
|Cash Flow from Ops. ⓘ||139||50.1||351||384||679||256||1,605||2,101||1,325||1,686||-|
|Debt/CF from Ops. ⓘ||6||24.2||5.1||17.2||10.3||42.8||5.8||4.1||6.5||5.1||-|
CAGR ⓘCAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||-22%||NA||NA||NA|
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||29.3||26.2||24||14.8||-3.7||-5.6||-8.9||-7.6||-7.3||1||6.7|
|Op. Profit Mgn % ⓘ||21||19.7||18.6||16.9||12.7||13.3||15.3||19||16||18.6||20.1|
|Net Profit Mgn % ⓘ||14.3||11.6||9.7||7.1||-2.1||-3.4||-6.9||-6.2||-4.9||0.6||1.5|
|Debt to Equity ⓘ||0.5||0.7||0.7||1.6||1.5||1.6||1.1||1.1||1.2||1.2||-|
|Working Cap Days ⓘ||196||232||239||274||355||360||364||359||344||329||0|
|Cash Conv. Cycle ⓘ||98||102||99||112||152||162||199||201||187||192||0|
No data to display
Return on Equity has declined versus last 3 years average to %
Sales growth has been subdued in last 3 years %
Sales growth is not so good in last 4 quarters at %
|TTM EPS (₹)||11.6||-30|
|TTM Sales (₹ Cr.)||12,239||9,623|
|BVPS (₹.) ⓘ||56.7||41.8|
|Reserves (₹ Cr.) ⓘ||855||622|
|From the Market|
|52 Week Low / High (₹)||208.80 / 211.00|
|All Time Low / High (₹)||0.42 / 312.80|
|Market Cap (₹ Cr.)||3,273|
|Equity (₹ Cr.)||31.3|
|Face Value (₹)||2|
|Industry PE ⓘ||38.1|
Matrix Laboratories (MLL), incorporated in the year 1985, is a subsidiary of US based company Mylan Inc. It is engaged in manufacturing of Active Pharmaceutical Ingredients (APIs) and Solid Oral Dosage Forms.
MLL has manufacturing facilities located in four locations in
Mylan Inc had acquired 71.5% stake in Matrix Laboratories in 2007 for USD 736 million. Since then, the US firm has successfully integrated the two organisations, along with the generics business of Merck KGaA, to build a global, high quality pharmaceutical platform with $5.5 billion revenues in 2010.
Matrix Laboratories is one of the worldâ€™s largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) for a wide range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.
August 2009 - Matrix becomes a privately held Mylan subsidiary
June 2009 - Mylan announces successful Matrix delisting offer
January 2007 - Mylan Laboratories acquires a 71.5% controlling interest in Matrix Laboratories Limited
January 2007 - Matrix receives â€œFastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2006
May 2006 - Matrix receives â€œBest Managementâ€ award from the government of Andhra Pradesh
December 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2005
December 2005 - Matrix announces decision to acquire controlling stake in Concord Biotech, an Ahmedabad-based biotechnology company with fermentation and bio-catalytic technology capabilities and U.S. Food and Drug Administration (FDA) approved API manufacturing facilities
November 2005 - Matrix receives the National Award for R&D Efforts in Industry for 2005 in Pharmaceuticals/Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology
June 2005 - Matrix Laboratories Limited acquires a controlling stake in Docpharma, based in Belgium
April 2005 - Matrix and Aspen Pharmacare Holdings Limited form joint ventures in India and South Africa
February 2005 - Matrix announces strategic alliance with MCHEM Pharma Group of China
January 2005 - Matrix receives 'Fastest Wealth Creator' award in Motilal Oswal Wealth Creation Study for 2004
January 2005 - Matrix purchases finished dosage facility located near Nashik, about 150 km from Mumbai
April 2004 - Matrix signs definitive agreements with India Newbridge Investments Limited and Maxwell (Mauritius) Pte. Limited
March 2004 - Matrixâ€™s Board of Directors approves the companyâ€™s merger with Vera Laboratories Limited, Fine Drugs and Chemicals Limited, Medikon Laboratories Limited and Calibre Engineering Private Limited
March 2004 - Matrix receives U.S. FDA approval for its manufacturing facility at Jeedimetla, near Hyderabad
November 2003 - Matrix sets up two 50:50 joint venture companies, one in India and the other in Ireland
October 2003 - Matrix signs an agreement with the William J. Clinton Foundation to supply ARVs for the treatment of HIV/AIDS patients in sub-Saharan Africa, South Africa and the Caribbean countries
May 2003 - Matrix merges with Vorin Laboratories Limited and Medicorp Technologies India Limited
April 2003 - Matrix successfully files process patent applications for four products at the Indian Patent Office
In the year 2006 the company received â€œBest Management Awardâ€ from the Government of Andhra Pradesh
It received National Award for R&D Efforts in Industry in Pharmaceuticals /Chemical Sector from the Department of Scientific & Industrial Research, Government of India, Ministry of Science and Technology in 2005.